All In MedTech

FDA Clearance Tracker · DEN190025

OraQuick Ebola Rapid Antigen Test

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 19, 2026Latest source record: Oct 10, 2019 (this decision)Source: openFDAMethods & limitations

De NovoNew device typeBreakthrough

Decided

Oct 10, 2019

De Novo granted

Time to decision

150 days

Received May 13, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN190025
Device name
OraQuick Ebola Rapid Antigen Test
Applicant location
Bethlehem, PA
Received
May 13, 2019
Decided
Oct 10, 2019
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 866.4002

Every decision under product code QID

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for OraSure Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.